Clinical Trials Browser

Phase 1/2 × DT2216 × 30 days × Clear all

NCT06620302 2026-02-24

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma